Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : A first-in-class novel peptide drug candidate against GPC3 is being developed where GPC3 drug candidate has demonstrated potent and selective GPC3 binding, rapid cellular internalization, and sustained tumor specific uptake and anti-tumor efficacy in pre...
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
March 31, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : 225-Ac
Therapeutic Area : Oncology
Study Phase : Undisclosed
Sponsor : Yonghe Pharma
Deal Size : Undisclosed
Deal Type : Agreement
Details : Actinium-225 is an alpha emitting radioactive particle that has high energy density acting at distances of just a few cell widths. At these short distances, radiation can be restricted to the cancer cells of interest with minimal risk to nearby normal he...
Product Name : Undisclosed
Product Type : Other Large Molecule
Upfront Cash : Undisclosed
December 27, 2022
Lead Product(s) : 225-Ac
Therapeutic Area : Oncology
Highest Development Status : Undisclosed
Sponsor : Yonghe Pharma
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : 225-Ac
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Vivo Capital
Deal Size : $75.0 million
Deal Type : Series A Financing
Details : Proceeds from the financing will be used by Ablaze to establish a leading pipeline of advanced TRT products having Actinium-225 for the treatment of solid tumors, build up infrastructure for radiopharmaceuticals and secure further strategic collaboration...
Product Name : Undisclosed
Product Type : Other Large Molecule
Upfront Cash : Undisclosed
November 29, 2021
Lead Product(s) : 225-Ac
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Vivo Capital
Deal Size : $75.0 million
Deal Type : Series A Financing